106 filings
8-K
THAR
Tharimmune, Inc.
16 Sep 24
Tharimmune Acquires Global License and Partners with Intract Pharma to Develop an Oral Formulation of Infliximab
9:06am
10-Q
2024 Q2
THAR
Tharimmune, Inc.
Quarterly report
9 Aug 24
3:09pm
424B3
THAR
Tharimmune, Inc.
23 Jul 24
Prospectus supplement
4:13pm
EFFECT
THAR
Tharimmune, Inc.
22 Jul 24
Notice of effectiveness
12:15am
S-3
THAR
Tharimmune, Inc.
Shelf registration
15 Jul 24
4:43pm
D
jape60
28 Jun 24
$2.08 mm in equity / options / securities to be acquired, sold $2.08 mm, 5 investors
5:25pm
8-K
q2pd ubm4
20 Jun 24
Tharimmune Announces $2.08 Million Private Placement
4:15pm
S-8
23ik9 pwxs
12 Jun 24
Registration of securities for employees
4:14pm
8-K
5kye6t 1c79d
11 Jun 24
Other Events
4:15pm
8-K
16zkrl2k8fl7ut9o2bo
7 Jun 24
Entry into a Material Definitive Agreement
5:23pm
424B5
5kn si0cog
7 Jun 24
Prospectus supplement for primary offering
5:21pm
8-K
fhz41oc o75p
22 May 24
Tharimmune Announces 1-for-15 Reverse Stock Split
4:15pm
8-K
af8eee62y1 0w3p2r
14 May 24
Submission of Matters to a Vote of Security Holders
4:30pm
DEFA14A
bml96n
22 Mar 24
Additional proxy soliciting materials
11:12am
ARS
gy8vr8p
22 Mar 24
Annual report to shareholders
11:08am
DEFA14A
nlwlhfs6
21 Mar 24
Additional proxy soliciting materials
5:27pm
8-K
aip5vic0b1c
11 Mar 24
Amendments to Articles of Incorporation or Bylaws
4:15pm